JP6682641B2 - αＫｌｏｔｈｏに対する抗体およびＥＬＩＳＡ - Google Patents

αＫｌｏｔｈｏに対する抗体およびＥＬＩＳＡ Download PDF

Info

Publication number
JP6682641B2
JP6682641B2 JP2018540464A JP2018540464A JP6682641B2 JP 6682641 B2 JP6682641 B2 JP 6682641B2 JP 2018540464 A JP2018540464 A JP 2018540464A JP 2018540464 A JP2018540464 A JP 2018540464A JP 6682641 B2 JP6682641 B2 JP 6682641B2
Authority
JP
Japan
Prior art keywords
cdr
seq
residues
αklotho
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018540464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513004A5 (enExample
JP2019513004A (ja
Inventor
ザッデブ、エス．シドゥ
サラ、エル．バーカー
オーソン、ダブリュ．モー
誠 黒尾
誠 黒尾
ヨハンネ、パストール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Toronto
University of Texas System
Original Assignee
University of Toronto
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Toronto, University of Texas System filed Critical University of Toronto
Publication of JP2019513004A publication Critical patent/JP2019513004A/ja
Publication of JP2019513004A5 publication Critical patent/JP2019513004A5/ja
Application granted granted Critical
Publication of JP6682641B2 publication Critical patent/JP6682641B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018540464A 2016-02-03 2017-02-03 αＫｌｏｔｈｏに対する抗体およびＥＬＩＳＡ Expired - Fee Related JP6682641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290776P 2016-02-03 2016-02-03
US62/290,776 2016-02-03
PCT/CA2017/050127 WO2017132772A1 (en) 2016-02-03 2017-02-03 Antibodies and elisas for alpha klotho

Publications (3)

Publication Number Publication Date
JP2019513004A JP2019513004A (ja) 2019-05-23
JP2019513004A5 JP2019513004A5 (enExample) 2020-03-19
JP6682641B2 true JP6682641B2 (ja) 2020-04-15

Family

ID=59499231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540464A Expired - Fee Related JP6682641B2 (ja) 2016-02-03 2017-02-03 αＫｌｏｔｈｏに対する抗体およびＥＬＩＳＡ

Country Status (5)

Country Link
US (2) US10663474B2 (enExample)
EP (1) EP3411482A4 (enExample)
JP (1) JP6682641B2 (enExample)
CA (1) CA3012873A1 (enExample)
WO (1) WO2017132772A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10228374B2 (en) 2014-07-31 2019-03-12 The Governng Council of the University of Toronto Antibodies with high affinity for alpha-Klotho
WO2017132772A1 (en) 2016-02-03 2017-08-10 The Governing Council Of The University Of Toronto Antibodies and elisas for alpha klotho
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN120943965A (zh) * 2025-10-16 2025-11-14 广东医科大学附属医院 一种αKL蛋白抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877081C (en) * 2011-09-27 2020-09-22 The Governing Council Of The University Of Toronto Molecular display method
WO2013184218A1 (en) 2012-06-05 2013-12-12 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
US10228374B2 (en) 2014-07-31 2019-03-12 The Governng Council of the University of Toronto Antibodies with high affinity for alpha-Klotho
US9697298B2 (en) 2014-08-07 2017-07-04 Etas Embedded Systems Canada Inc. ID tag authentication system and method
CN107614020A (zh) 2015-03-18 2018-01-19 免疫生化公司 靶向细胞内肿瘤相关抗原的用于治疗癌症的缀合物
WO2017132772A1 (en) 2016-02-03 2017-08-10 The Governing Council Of The University Of Toronto Antibodies and elisas for alpha klotho

Also Published As

Publication number Publication date
WO2017132772A1 (en) 2017-08-10
EP3411482A4 (en) 2019-12-11
US20200300867A1 (en) 2020-09-24
US11143661B2 (en) 2021-10-12
US10663474B2 (en) 2020-05-26
CA3012873A1 (en) 2017-08-10
EP3411482A1 (en) 2018-12-12
US20190041402A1 (en) 2019-02-07
JP2019513004A (ja) 2019-05-23

Similar Documents

Publication Publication Date Title
JP6612324B2 (ja) αＫｌｏｔｈｏに対して高親和性を有する抗体
JP6948415B2 (ja) 抗ｇｐ７３モノクローナル抗体およびそれを得る方法
CN106574258B (zh) 抗-运甲状腺素蛋白人源化抗体
DK2732289T3 (en) ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS
US11143661B2 (en) Antibodies that specifically bind alpha klotho
US20220056118A1 (en) Antibodies to misfolded tdp-43 and methods of use
KR102795552B1 (ko) 트립토파닐-티알엔에이 합성효소 단백질에 특이적으로 결합하는 항체 및 이의 용도
CN117500828A (zh) 结合VEGF和Ang2的双特异性结合分子以及其用途
US20230174630A1 (en) Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use
JP2023086132A (ja) アミロイドベータに対する抗体
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
CN113754763A (zh) 分离的抗原结合蛋白及其用途
AU2019356804B2 (en) Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof
JP7453694B2 (ja) 細胞外膜に露出されるリシル－ｔＲＮＡ合成酵素のＮ－末端領域に特異的に結合する抗体
KR20160093502A (ko) 항 eprs 모노클로날 항체 및 이의 용도
JP2025082818A (ja) 遺伝子組換え抗体、それを含むキット、およびがん診断におけるその使用
EA045911B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200204

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200204

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200325

R150 Certificate of patent or registration of utility model

Ref document number: 6682641

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees